Hansen Medical, Inc.
http://www.hansenmedical.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hansen Medical, Inc.
Aurobindo One Step Closer To Xolair Biosimilar Registration
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
Celltrion Leads Xolair Biosimilar Race With US FDA Application
This marks Celltrion’s second regulatory submission for an omalizumab biosimilar as the US formulation patent protecting originator Xolair is set to expire late next year.
Applied Therapeutics Takes Strong Swipe At SORD With Govorestat
Govorestat could soon be filed for a second indication after impressing as a potential treatment for SORD deficiency, one of the most common forms of recessive hereditary neuropathy for which there are no approved therapies.
Deals Abound At Advanz
Advanz has acquired exclusive rights to register and commercialize a Phase III candidate from Dimerix in multiple territories, alongside agreements with Kyowa Kirin, Bayer and GP Pharm.
Company Information
- Industry
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice